Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.
Advertisement

Related Content

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half
Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half
Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
Gilead Submits NDA For Ambrisentan For PAH

Topics

Advertisement
UsernamePublicRestriction

Register

PS065640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel